BioSig Technologies, Inc.

  • Home
  • About BioSig
    • Overview
    • Leadership
    • Bioelectronic Medicine
    • Partnerships
  • Pure EP
    • Our Solution
    • Publications
    • Physician Insights
  • Join Our Team
    • Join Our Team
    • Working at Biosig
    • Discover Your Potential
  • News & Media
    • Overview
    • Press Releases
    • BioSig in the News
    • Presentations
    • Events
    • CEO Blog
    • Newsletter
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
    • Company Info
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • NeuroClear
  • Contact
News & Media

News & Media

  • Overview
  • Press Releases
  • BioSig in the News
  • Presentations
  • Events
  • CEO Blog
  • Newsletter

Press Releases

BioSig Technologies’s PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions

June 4, 2020

BioSig Technologies Expands Intellectual Property Portfolio

June 3, 2020

ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-viral Candidate for Treatment of COVID-19

June 1, 2020

Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

May 28, 2020

ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib

May 20, 2020

FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClear’s Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19, to Proceed

May 18, 2020

ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy between Merimepodib and Remdesivir Against SARS-CoV-2, the Cause of COVID-19

May 14, 2020

Biotech and Investment Veteran Dennis Purcell Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

May 5, 2020

BioSig Resumes Clinical Activities with PURE EP System

May 1, 2020

ViralClear Submits In Vitro Data on Merimepodib and Remdesivir Synergistic Activity Against the COVID-19 Novel Coronavirus to a Peer-Reviewed Journal

April 30, 2020
    • 1...
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • ...30
    Award
    BioSig Technologies, Inc.
    Sign Up for BioSig Updates Contact Us
    Twitter linkedin Facebook
    © 2022 BioSig Technologies, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap